Aclarubicin-associated QTc prolongation and ventricular fibrillation.
A marked prolongation of QTc (corrected QT interval for heart rate) in ECG developed in two patients with acute leukemia during induction chemotherapy with aclarubicin, one of the anthracycline antibiotics. This ECG change was followed by ventricular fibrillation. No signs or symptoms of congestive heart failure were noted. The outcome in one case was fatal; in the other case, the ECG change was reversible. These observations suggest that QTc prolongation, which has been considered to be a sign of acute cardiotoxicity of anthracycline derivatives, may signal a clinical risk of ventricular fibrillation.
D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D014693:Ventricular Fibrillation / Q000139:chemically induced*
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin